Ann: App 4E / Full Year Statutory Accounts, page-46

I think you'll find the original dosing comments, ahem, enlightening:

The primary end-point for the clinical trial will be to assess safety and tolerance of TT-034 in HCV-infected patients. Benitec expects to report a preliminary assessment of safety data to the ASX throughout the clinical trial on the following basis:

• Notification that the second patient in the trial has been dosed;
• Dosing of the first patient in the second cohort, along with comments on the first cohort;
• Dosing of the first patient in the third cohort, along with comments on the second cohort;
• Dosing of the first patient in the fourth cohort, along with comments on the third cohort; and
• Dosing of the first patient in the fifth cohort, along with comments on the fourth cohort.

Notwithstanding this anticipated schedule, the Company will provide an update to the ASX at any time should a material event occur that relates to the clinical trial.

http://www.irasia.com/listco/au/benitec/press/p140711.htm